Synonyms: BVL-GSK098
Compound class:
Synthetic organic
Comment: Alpibectir is being developed by BioVersys AG and GlaxoSmithKline as an oral treatment for tuberculosis (TB) in combination with ethionamide or prothionamide. Alpibectir targets bacterial transcriptional regulators and potentiates the activity of drugs used in the treatment of TB, in particular drugs that are activatable via the EthA pathway. It is one of the spiroisoxazoline class of compounds claimed in patent WO2019034700A1 [1].
|
|
References |
1. De Francisco EP, Remuinan-Blanco MJ, Bourotte M, Deprez B , Willand N. (2019)
Novel compounds. Patent number: WO2019034700A1. Assignee: GlaxoSmithKline, BioVersys. Priority date: 15/08/2018. Publication date: 21/02/2019. |
2. Maitre T, Baulard A, Aubry A, Veziris N. (2024)
Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis. Infect Dis Now, 54 (1): 104807. [PMID:37839674] |